WO2010079998A3 - 진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도 - Google Patents

진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도 Download PDF

Info

Publication number
WO2010079998A3
WO2010079998A3 PCT/KR2010/000137 KR2010000137W WO2010079998A3 WO 2010079998 A3 WO2010079998 A3 WO 2010079998A3 KR 2010000137 W KR2010000137 W KR 2010000137W WO 2010079998 A3 WO2010079998 A3 WO 2010079998A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
ras
hog
increases
ergosterol
Prior art date
Application number
PCT/KR2010/000137
Other languages
English (en)
French (fr)
Other versions
WO2010079998A2 (ko
Inventor
반용선
고영준
맹신애
정광우
김규범
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090001947A external-priority patent/KR101079278B1/ko
Priority claimed from KR1020090127206A external-priority patent/KR101167988B1/ko
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to US13/143,921 priority Critical patent/US20120093817A1/en
Publication of WO2010079998A2 publication Critical patent/WO2010079998A2/ko
Publication of WO2010079998A3 publication Critical patent/WO2010079998A3/ko
Priority to US13/862,666 priority patent/US9017956B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 진균 감염의 치료를 위한 HOG, Ras 및 cAMP 신호전달경로 유전자의 용도를 제공한다. 본 발명에서는 크립토코쿠스 네오포만스의 HOG 경로 조절에 있어서 SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 및 NHA1 유전자들이 수행하는 역할에 대해 조사하여, 이들 유전자들이 억제되면 에르고스테롤의 생합성량이 증진됨을 새로이 밝혀냈다. 상기 유전자들을 억제하면 진균의 세포막 상에 에르고스테롤이 다량 분포하게 되므로, 에르고스테롤-결합성 항진균제의 작용점이 많아서 에르고스테롤-결합성 항진균제의 효능을 현저히 상승시킬 수 있게 된다. 또한 본 발명에서는 크립토코쿠스 네오포만스의 Ras 및 cAMP 경로의 조절에 있어서 RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 및 HSP122 유전자들이 수행하는 역할에 대해 조사하여, 이들 유전자들이 억제되면 폴리엔계 약물이나 아졸계 약물에 대한 감수성이 증진됨을 새로이 밝혀냈다. 따라서 상기 유전자 또는 이들에 의해 코딩되는 단백질에 대한 저해제를 포함하는 항진균용 의약 조성물은 기존 항진균제의 사용 용량을 절감시키면서 효능을 상승시킬 수 있는 우수한 복합 항균치료제로서 사용할 수 있다.
PCT/KR2010/000137 2009-01-09 2010-01-08 진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도 WO2010079998A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/143,921 US20120093817A1 (en) 2009-01-09 2010-01-08 USE OF THE GENES IN THE HOG, Ras AND cAMP PATHWAY FOR TREATMENT OF FUNGAL INFECTION
US13/862,666 US9017956B2 (en) 2009-01-09 2013-04-15 Use of the genes in the Hog, Ras and cAMP pathway for treatment of fungal infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020090001947A KR101079278B1 (ko) 2009-01-09 2009-01-09 진균 감염의 치료를 위한 ｈｏｇ 신호전달경로 유전자의 용도
KR10-2009-0001947 2009-01-09
KR10-2009-0127206 2009-12-18
KR1020090127206A KR101167988B1 (ko) 2009-12-18 2009-12-18 진균 감염의 치료를 위한 Ｒａｓ 및 ｃＡＭＰ 신호전달경로 유전자의 용도

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/143,921 A-371-Of-International US20120093817A1 (en) 2009-01-09 2010-01-08 USE OF THE GENES IN THE HOG, Ras AND cAMP PATHWAY FOR TREATMENT OF FUNGAL INFECTION
US13/862,666 Continuation US9017956B2 (en) 2009-01-09 2013-04-15 Use of the genes in the Hog, Ras and cAMP pathway for treatment of fungal infection

Publications (2)

Publication Number Publication Date
WO2010079998A2 WO2010079998A2 (ko) 2010-07-15
WO2010079998A3 true WO2010079998A3 (ko) 2010-11-04

Family

ID=42317011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000137 WO2010079998A2 (ko) 2009-01-09 2010-01-08 진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도

Country Status (2)

Country Link
US (2) US20120093817A1 (ko)
WO (1) WO2010079998A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
ES2963511T3 (es) * 2015-03-30 2024-03-27 Amtixbio Co Ltd Nuevo gen que regula la virulencia de Cryptococcus neoformans, y utilización del mismo
KR20170054190A (ko) * 2015-11-09 2017-05-17 (주)앰틱스바이오 진균 감염 치료 및 예방을 위한 신규한 키나아제 및 이들의 용도
KR20220097423A (ko) * 2019-09-18 2022-07-07 (주)앰틱스바이오 뇌수막뇌염 유발 진균의 뇌-혈관 장벽 통과 및 뇌-내부 생존 관련 유전자의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293381A1 (en) * 2005-06-23 2006-12-28 Kaihei Kojima Fungicidal effect by regulating signal transduction pathways

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123780A1 (en) * 1991-12-11 1993-06-24 Ronald A. Pieringer Amphotericin b composition with enhanced antifungal activity
US6660761B2 (en) * 2002-02-06 2003-12-09 Council Of Scientific And Industrial Research Method of treatment for fungal infections with a synergistic formulation of antifungal agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293381A1 (en) * 2005-06-23 2006-12-28 Kaihei Kojima Fungicidal effect by regulating signal transduction pathways

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAHN Y. S. ET AL.: "A unique fungal two-component system regulates stress responses, drug sensitivity, sexual development, and virulence of Cryptococcus neoformans.", MOL. BIOL. CELL., vol. 17, no. 7, 3 May 2006 (2006-05-03), pages 3122 - 3135 *
KOJIMA K. ET AL.: "Calcineurin, Mpkl and Hog MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans.", MICROBIOLOGY, vol. 152, March 2006 (2006-03-01), pages 591 - 604 *
KONTOYIANNIS D. P. ET AL.: "Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.", ANTIMICROB AGENTS CHEMOTHER., vol. 52, no. 2, 10 December 2007 (2007-12-10), pages 735 - 738 *

Also Published As

Publication number Publication date
US9017956B2 (en) 2015-04-28
US20120093817A1 (en) 2012-04-19
US20130237446A1 (en) 2013-09-12
WO2010079998A2 (ko) 2010-07-15

Similar Documents

Publication Publication Date Title
Bairwa et al. Iron acquisition in fungal pathogens of humans
Li et al. Promising antifungal targets against Candida albicans based on ion homeostasis
Delattin et al. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms
WO2012119065A3 (en) Antifungal agents and uses thereof
He et al. Protective role of apigenin in cisplatin-induced renal injury
ES2798775T3 (es) Uso de oligómeros de alginato para reforzar los efectos de agentes antifúngicos
CN103704215B (zh) 一种含壳寡糖的杀菌组合物
WO2011130753A3 (en) Functionalized nano- and micro-materials for medical therapies
WO2007098611A8 (en) Compositions for treatment of cancer
WO2012156317A3 (en) Intranasal pharmaceutical dosage forms comprising naloxone
WO2010079998A3 (ko) 진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도
WO2008129548A3 (en) A system for delivering therapeutic agents into living cells and cells nuclei
MX2011012513A (es) Metodos para tratar cancer y estados no neoplasicos.
WO2012076670A3 (en) Antibody formulation
WO2009105624A3 (en) Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
WO2009045291A3 (en) Mast cell stabilizers in the treatment of obesity
WO2013148686A3 (en) Stable igg4 binding agent formulations
Zhang et al. κ-opioid receptor activation protects against myocardial ischemia-reperfusion injury via AMPK/Akt/eNOS signaling activation
WO2012058675A3 (en) Zinc oxide complexes
WO2009106819A3 (en) Biological materials and uses thereof
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
Giacobbe et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections
WO2010025859A3 (de) Stabilisierung von zellen durch ionische flüssigkeiten
WO2013027988A3 (ko) 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
WO2009069935A3 (en) Pharmaceutical compositions and methods for delivering nucleic acids into cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10729340

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13143921

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10729340

Country of ref document: EP

Kind code of ref document: A2